Quoin reports QRX003 clears skin in pediatric Netherton syndrome case study
QNRX•Quoin Pharmaceuticals reported that a child’s severe skin symptoms largely cleared and itching resolved during 21 months of compassionate-use treatment with QRX003. No treatment-related adverse events were reported, but the findings are from a single patient.
1. Case study findings
A peer-reviewed case report published in Dermatology and Therapy on October 13, 2026, described a pediatric Netherton syndrome patient whose severe skin symptoms largely cleared during 21 months of compassionate-use treatment with QRX003. The patient’s itching resolved, and no treatment-related adverse events were reported. The single-patient findings require further evaluation in clinical trials.
2. Trial timeline
Quoin said positive interim Phase 2/3 results reported in August showed skin improvement in most evaluated participants. The company expects to recruit all 20 participants by year-end 2026, with topline results due in the second quarter of 2027.
